Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has provided an update.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 9, 2025, to discuss significant changes including the abolishment of the Supervisory Board and amendments to the Articles of Association. These proposals, if approved, could streamline the company’s governance structure and potentially impact its operational efficiency and shareholder engagement.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry in China, focusing on the development, manufacturing, and distribution of pharmaceutical products.
Average Trading Volume: 3,317,118
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.18B
See more insights into 2607 stock on TipRanks’ Stock Analysis page.